Cancer Research

Pharma company announces results from two clinical trials

Published in Biotech Business Week, December 20th, 2004

Pharmacyclics, Inc., (NASDAQ:PCYC) announced the presentation of results from two phase 1 clinical trials of Xcytrin (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, plus cranial irradiation for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common primary brain tumor in adults.

The presentation occurred at the 9th Annual Meeting of the Society for Neuro-Oncology (SNO) in Toronto, Canada.

The oral presentation entitled, "Cumulative Dose of Motexafin Gadolinium (MGd) and Survival in Newly Diagnosed Glioblastoma Multiforme (GBM)," was presented by See-Chun Phan, MD, a medical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry